Esmolol hydrochloride side effects by duration, gender and age - a phase IV clinical study of FDA data

< 1 month:

1. Confusional state
2. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
3. Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)
4. Blood glucose increased
5. Cerebral haemorrhage (bleeding within the brain)
6. Myocarditis (inflammation of heart muscle myocardium)
7. Pneumonia
8. Body temperature increased
9. Burkholderia test positive
10. Cardiac failure acute

1 - 6 months:

1. Hepatomegaly (abnormal enlargement of the liver)
2. Hepatotoxicity (chemical-driven liver damage)

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Drug ineffective
2. Death
3. Cardiac arrest
4. Abdominal distension
5. Arrhythmia (irregular heartbeat)
6. Bradycardia (abnormally slow heart action)
7. Extravasation (leakage of a fluid)
8. Acute hepatic failure
9. Acute myocardial infarction (acute heart attack)
10. Acute respiratory failure

female:

1. Drug ineffective
2. Cerebral haemorrhage (bleeding within the brain)
3. Myocarditis (inflammation of heart muscle myocardium)
4. Pneumonia
5. Arrhythmia (irregular heartbeat)
6. Body temperature increased
7. Bradycardia (abnormally slow heart action)
8. Cardiac arrest
9. Cardiac failure
10. Cardiac failure acute

male:

1. Hepatomegaly (abnormal enlargement of the liver)
2. Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)
3. Blood catecholamines increased
4. Blood pressure decreased
5. Bradycardia (abnormally slow heart action)
6. Burkholderia test positive
7. Cardiac arrest
8. Cardiac output decreased
9. Cardiogenic shock (inadequate circulation of blood)
10. Confusional state

0-1:

1. Bradycardia (abnormally slow heart action)
2. Cardiac output decreased
3. Drug ineffective

2-9:

1. Hepatomegaly (abnormal enlargement of the liver)
2. Hepatotoxicity (chemical-driven liver damage)

10-19:

1. Anaphylactic reaction (serious allergic reaction)
2. Blood catecholamines increased
3. Cardiac failure

20-29:

1. Cardiac arrest
2. Cardiogenic shock (inadequate circulation of blood)
3. Drug ineffective

30-39:

1. Blood glucose increased
2. Abdominal distension
3. Acute hepatic failure
4. Cardiac arrest
5. Drug ineffective
6. Maternal exposure during pregnancy (use of substance during pregnancy)
7. Oxygen saturation decreased
8. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)
9. Seizure (abnormal excessive or synchronous neuronal activity in the brain)

40-49:

n/a

50-59:

1. Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)
2. Drug ineffective
3. Myocarditis (inflammation of heart muscle myocardium)
4. Pneumonia
5. Acute respiratory failure
6. Blood pressure decreased
7. Body temperature increased
8. Disease progression
9. Extravasation (leakage of a fluid)

60+:

1. Cerebral haemorrhage (bleeding within the brain)
2. Drug ineffective
3. Arrhythmia (irregular heartbeat)
4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
5. Cardiac failure acute
6. Confusional state
7. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
8. Hypotension (abnormally low blood pressure)
9. Multi-organ failure (multisystem organ failure)
10. Sepsis (a severe blood infection that can lead to organ failure and death)